Erin Macrae
Columbus Oncology and Hematology Associates(US)The Ohio State University(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Cancer Cells and Metastasis, Cancer Genomics and Diagnostics, Advanced Breast Cancer Therapies
Most-Cited Works
- → Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline(2016)635 cited
- → Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H(2020)287 cited
- → Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients(2014)121 cited
- → Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer(2017)71 cited
- → Use and Duration of Chemotherapy in Patients With Metastatic Breast Cancer According to Tumor Subtype and Line of Therapy(2014)47 cited
- → Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials(2015)47 cited
- → Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer(2014)44 cited
- → Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update(2024)43 cited
- → Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo(2015)32 cited
- → Discovery of Stromal Regulatory Networks that Suppress Ras-Sensitized Epithelial Cell Proliferation(2017)29 cited